AI Terminal
ARECOR THERAPEUTICS PLC
AGM Information • Jun 2, 2025
7494_agm-r_2025-06-02_dda30c7b-219f-45e3-a8d6-123369eb7b1e.html
AGM Information
Open in ViewerOpens in native device viewer
National Storage Mechanism | Additional information 
RNS Number : 0564L
Arecor Therapeutics PLC
02 June 2025
Arecor Therapeutics plc
("Arecor", the "Company" or the "Group")
RESULT OF AGM
Cambridge, UK, 2 June 2024: Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical company advancing today's therapies to enable healthier lives, announces that at its Annual General Meeting, held today at 09.30 am, all eleven resolutions put to members were passed. Resolution 8 was made redundant and bypassed.
The full text of each resolution was included in the Company's Notice of Annual General Meeting made available on the Company's website .
The number of proxy votes cast for and against each of the resolutions proposed, and the number of proxy votes withheld were as follows:
| Resolution | Votes for | % | Votes against | % | Votes withheld |
| Resolution 1 To receive the directors' report, the consolidated financial statements and the auditors' report for the year ended 31 December 2024 |
17,521,432 | 100 | 0 | 0 | 174,884 |
| Resolution 2 To approve the directors' remuneration report as set out on pages 36 to 38 in the annual report for the year ended 31 December 2024 |
15,574,064 | 91.31 | 1,481,955 | 8.69 | 640,297 |
| Resolution 3 To re-elect Sarah Howell as a Director of the Company in accordance with the articles |
17,547,867 | 100 | 0 | 0 | 148,449 |
| Resolution 4 To re-elect Andrew Richards as a Director of the company in accordance with the articles |
16,586,103 | 94.52 | 961,764 | 5.48 | 148,449 |
| Resolution 5 To re-elect Sam Fazeli as a Director of the Company in accordance with the articles |
15,881,200 | 90.50 | 1,666,667 | 9.50 | 148,449 |
| Resolution 6 To re-elect Jeremy Morgan as a Director of the Company in accordance with the articles |
17,547,867 | 100 | 0 | 0 | 148,449 |
| Resolution 7 To re-elect Christine Soden as a Director of the Company in accordance with the articles |
17,547,867 | 100 | 0 | 0 | 148,449 |
| Resolution 8 To re-elect Alan Smith as a Director of the Company is redundant and was bypassed. |
|||||
| Resolution 9 To re-appoint Grant Thornton as auditors of the Company |
17,525,016 | 99.88 | 21,620 | 0.12 | 149,680 |
| Resolution 10 To authorise the Directors to agree the auditors' remuneration |
17,537,747 | 99.94 | 10,120 | 0.06 | 148,449 |
| Resolution 11 To authorise the allotment of shares |
16,580,991 | 99.60 | 67,376 | 0.40 | 1,047,949 |
| Resolution 12 (special) To disapply statutory pre-emption rights |
16,580,842 | 99.93 | 11,500 | 0.07 | 1,103,974 |
-ENDS-
For more information, please contact:
| Arecor Therapeutics plc | www.arecor.com |
| Dr Sarah Howell, Chief Executive Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| David Ellam, Chief Financial Officer | Tel: +44 (0) 1223 426060 Email: [email protected] |
| Singer Capital Markets Advisory LLP (NOMAD and Broker) | |
| Phil Davies, Sam Butcher | Tel: +44 (0) 20 7496 3000 |
| ICR Healthcare | |
| Chris Gardner, David Daley, Lindsey Neville | Tel: +44 (0) 20 3709 5700 Email: [email protected] |
Notes to Editors
About Arecor
Arecor Therapeutics plc is a globally focused biopharmaceutical company transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying our innovative proprietary technology platform, Arestat™, we are developing an internal portfolio of proprietary products in diabetes and other indications, as well as working with leading pharmaceutical and biotechnology companies to deliver therapeutic products. The Arestat™ platform is supported by an extensive patent portfolio. For further details please see our website, www.arecor.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGPKBBBBBKDPAK